CIPLA LTD vs JAGSONPAL PHARMACEUTICALS
A side-by-side comparison of CIPLA LTD (CIPLA) and JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads CIPLA vs JAGSNPHARM on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation31
- Profitability13
- Growth11
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
CIPLA takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
JAGSNPHARM takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 50.3%", "Promoter holding has increased by 1.17% over last quarter.", "Company's working capital requirements have reduced from 24.0 days to 11.0 days"]
- − ["The company has delivered a poor sales growth of 8.85% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.